Revenue ($USD): $847,133,000 R&D spend: $79,407,000.00 Employees: 3,900 Fiscal year end: 12/31/22 CEO: Adam Elsesser
Penumbra was founded in 2004 by President, Chair and CEO Adam Elsesser and Dr. Arani Bose, who formerly served as chair, chief medical officer and chief innovator.Penumbra develops interventional devices for vascular and neuro therapies, including catheters, coils and clot retrievers. Recent FDA clearances include theLightning Flash mechanical thrombectomy system in 2022and the Lightning Bolt 7 arterial thrombectomy system in 2023. However, the launch of the Thunderbolt mechanical thrombectomy system will likely be delayed until 2024.–JH